| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 43.515 | 68.683 | 180.345 | 387.873 | 363.834 | 273.231 | 422.171 | 466.935 | 586.824 | 712.524 |
| Total Income - EUR | 44.969 | 83.333 | 180.713 | 387.908 | 371.029 | 279.563 | 423.384 | 472.917 | 589.347 | 714.180 |
| Total Expenses - EUR | 61.490 | 61.847 | 85.168 | 190.462 | 264.002 | 249.883 | 323.357 | 352.652 | 428.836 | 456.529 |
| Gross Profit/Loss - EUR | -16.521 | 21.486 | 95.545 | 197.446 | 107.027 | 29.680 | 100.026 | 120.265 | 160.510 | 257.651 |
| Net Profit/Loss - EUR | -16.521 | 20.660 | 93.737 | 193.570 | 103.330 | 27.111 | 95.882 | 115.651 | 149.636 | 220.565 |
| Employees | 6 | 5 | 4 | 4 | 5 | 5 | 4 | 5 | 6 | 5 |
Check the financial reports for the company - Prof Medica Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.907 | 8.134 | 64.672 | 56.838 | 118.447 | 85.926 | 57.663 | 26.806 | 91.389 | 87.462 |
| Current Assets | 125.459 | 60.388 | 97.522 | 276.141 | 337.865 | 367.858 | 264.628 | 256.864 | 214.678 | 324.492 |
| Inventories | 0 | 0 | 1.804 | 7.549 | 22.363 | 602 | 3.112 | 1.295 | 0 | 0 |
| Receivables | 9.038 | 5.642 | 4.927 | 11.769 | 4.012 | 9.300 | 2.785 | 9.957 | 6.763 | 4.539 |
| Cash | 116.421 | 54.746 | 90.790 | 256.823 | 311.490 | 357.956 | 258.732 | 245.612 | 207.915 | 319.953 |
| Shareholders Funds | 124.976 | 66.882 | 159.488 | 321.616 | 418.718 | 437.891 | 129.775 | 149.649 | 183.530 | 254.270 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | 202 | 201 |
| Debts | 4.463 | 1.720 | 2.707 | 11.363 | 37.753 | 16.140 | 192.516 | 134.170 | 122.951 | 157.836 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Prof Medica Srl